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Abstract Annexins are widely distributed and have been de-
scribed in lung as well as in other cells and tissues. Annexin I
(ANX AI) is a member of the calcium-dependent phospholipid
binding protein family. Besides its anti-in£ammatory function,
ANX AI has been involved in several mechanisms such as the
Erk repression pathway or apoptosis. To investigate the role of
ANX AI on apoptosis in broncho-alveolar cells, we have con-
structed a plasmid containing the ANX AI full length cDNA.
Transfected BZR cells displayed a higher level of both forms of
ANX AI (37 and 33 kDa) as well as a decrease in cell viability
(two-fold versus cells transfected with an empty vector). In order
to analyse the endogenous ANX AI processing during stimulus-
induced apoptosis, BZR cells were treated with a commonly
used inducer, i.e. C2 ceramides. In these conditions, microscopic
analysis revealed chromatin condensation in dying cells and the
Bcl-2, Bcl-xL/Bax mRNA balance was altered. Caspase-3 is one
of the key executioners of apoptosis, being responsible for the
cleavage of many proteins such as the nuclear enzyme poly-
(ADP-ribose) polymerase (PARP). We demonstrate that cas-
pase-3 was activated after 4 h treatment in the presence of
ceramide leading to the cleavage of PARP. Dose^response ex-
periments revealed that cell morphology and viability modi¢ca-
tions following ceramide treatment were accompanied by an
increase in endogenous ANX AI processing. Interestingly, in
both ceramide and transfection experiments, the ANX AI
cleaved form was enhanced whereas pre-treatment with the cas-
pase inhibitor Z-VAD-fmk abolished ANX AI cleavage. In con-
clusion, this study demonstrates a complex regulatory role of
caspase-dependent apoptosis where ANX AI is processed at the
N-terminal region which could give susceptibility to apoptosis
upon ceramide treatment.
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1. Introduction
Structurally annexin AI (ANX AI) belongs to a family of
ubiquitous phospholipid and calcium binding proteins. These
proteins were initially described as potent inhibitors of phos-
pholipase A2 (PLA2) activity whose synthesis is controlled by
glucocorticoid synthetic hormones [1,2]. Later, ANX AI was
implicated in several processes, of which some of the more
attractive proposals include their involvement in the regula-
tion of membrane tra⁄cking and exocytosis [3,4], the media-
tion of cytoskeleton^membrane interactions [5,6], mitogenic
signal transduction, cell proliferation and di¡erentiation [7^
12] as well as apoptosis [13,14]. However, despite detailed
structural information, the biological functions of annexins
are not clearly de¢ned in vivo.
Apoptosis is an essential, highly conserved, and tightly
regulated cellular process of cell death that is important for
development, host defence and suppression of malignant
transformation and in£ammatory processes. Keeping apopto-
sis under control limits the survival of deranged cells, reducing
the in£ammatory processes. Membrane lipids of the sphingo-
lipid class have long been assumed to be a mechanical barrier
to the extracellular environment. However, it has been shown
that ceramides, a second messenger [15], can be activated by
receptor-mediated mechanisms [16], and play an essential role
in cell growth, survival and death [17,18]. Indeed, ceramide
has been shown to induce apoptosis in a number of di¡erent
systems. Ceramide mediates apoptosis induced by environ-
mental stresses, chemotherapeutic agents or by the tumor ne-
crosis factor K receptor superfamily. Ceramide mimics the Fas
pathway through Ras and mitogen-activated protein kinase
(MAPK) phosphorylation, caspase activation and cell death.
The bronchial epithelium represents the last anatomic bar-
rier between host and aggressive agents responsible for in£am-
matory and immunological reactions. Chronic in£ammation
diseases, such as cystic ¢brosis, implicate ANX AI recruitment
to antagonise the pyrogenic activity of cytokines [19,20]. In
these conditions, a 33 kDa truncated form of ANX AI has
been found in broncho-alveolar lavage £uid from patients
next to protease activation [21]. Large amounts of ANX AI
have also been observed in pulmonary metastasis [22]. Be-
cause of its high degree of vascularisation, the bronchial ep-
ithelium is an easy target for such secondary tumours. With
regard to the importance of ANX AI in lung diseases, we
have investigated the regulation of this protein in a bron-
cho-alveolar cell line, BZR cells, and its relationship with
the apoptotic phenotype. Thus, we have demonstrated that
caspase activation is associated with a limited proteolysis of
ANX AI in BZR cells.
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2. Materials and methods
The biochemical reagents used in this study were purchased from
Sigma, France, except where stated otherwise.
2.1. Cell culture conditions
The broncho-alveolar epithelial cell line BZR (ATCC CRL-9483)
was kindly provided by Dr J.M. Polette (INSERM U 514, Reims,
France). Adherent cells were maintained in continuous culture at
37‡C, 5% CO2 in Dulbecco’s modi¢ed Eagle’s medium (DMEM)
(Gibco BRL, Life Technology) supplemented with 10% (v/v) heat-
inactivated foetal bovine serum (FBS) (Dutscher, France), 100 U/ml
penicillin, 100 Wg/ml streptomycin.
For the assays, con£uent monolayers of BZR cells were washed
twice with phosphate-bu¡ered saline (PBS), and trypsin EDTA solu-
tion was added to detach the cells. DMEM containing 10% FBS to
neutralise the trypsin was added to the detached cells, which were
centrifuged at 400Ug for 5 min. The cells were then resuspended in
DMEM plus 10% FBS. BZR cells were seeded into six-well plates at
0.2U106 cells per well and incubated overnight at 37‡C, 5% CO2. The
wells were rinsed twice with DMEM without FBS prior to treatment.
2.2. Experimental procedures
C2 ceramide, or C2 dehydroceramide (control) solutions (cat. no.
110145 and 219537, Calbiochem, France) were added to culture me-
dium at a concentration from 5 WM to 60 WM in fresh medium, and
incubated at 37‡C for varying times.
Caspase inhibitor (Z-VAD-fmk, cat. no. G7231/2, Promega,
France) was added 1 h before the addition of C2 ceramide, and
maintained in the medium until the cells were harvested.
2.3. Ceramide extraction and analysis
Lipids were extracted in chloroform/methanol (2:1, v/v) and puri-
¢ed by column and thin layer chromatography according to Leray et
al. [23]. Brie£y, the lipid extract was fractionated on a 300 mg silicic
acid column. The neutral lipids were eluted with 10 ml of chloroform,
glycolipids, which contain ceramides, with 15 ml of acetone/methanol
(9:1, v/v), and phospholipids with 10 ml of methanol. Ceramides were
analysed on borate-impregnated LK5 plates (Whatman, Clifton, NJ,
USA) with chloroform/ethanol/water/triethylamine (30/35/7/35, v/v) as
the eluent and subsequently sprayed with 20% (v/v) H2SO4 solution in
water. Ceramides were then visualised by charring during 15 min at
180‡C.
2.4. Determination of cytotoxicity
The cytotoxic e¡ect was evaluated directly on six-well culture plates
using the tetrazolium-based 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) assay [24].
2.5. Determination of apoptosis
The degree of chromatin condensation was determined by £uores-
cent staining of living and dead cells by the use of the dye Hoechst
33258 on cells cultivated on six-well plates following the protocol
given by the manufacturer (Molecular Probes).
For FACS analysis, cells were seeded in 75-cm2 £asks and treated
with C2 ceramide at a dose of 40 WM. After a period spanning 6^12 h,
cells were washed twice with cold PBS and resuspended in bu¡er at
a concentration of 5U106/ml: 5U105 cells were mixed with 2 Wl
of £uorescein isothiocyanate (FITC)-conjugated ANX V antibody
(Roche Diagnostics, Mannheim, Germany) and 2 Wl of 1 mg/ml pro-
pidium iodide (PI). After 15 min incubation at room temperature in
the dark, and further washes, cells were diluted at a concentration of
105/ml. Samples were analysed by £ow cytometry with a FACS ana-
lyser (FACSCalibur, Becton Dickinson) and a computer station run-
ning CellQuest software. ANX V staining was detected in the FL1
(green) channel, whereas PI staining was monitored in the FL2 (red)
channel: appropriate quadrants were set and the percentages of cells
negative for both stains (viable cells), positive for ANX V (apoptotic
cells) and positive for PI (dead cells) were acquired.
Apoptosis was con¢rmed with mRNA and protein analyses.
2.6. Isolation of total RNA and mRNA expression studies (RT-PCR)
Total RNA was isolated from BZR cells using the TRIzol reagent
(Invitrogen Life Technologies, Cergy Pontoise, France) following the
manufacturer’s recommendations and analysed on agarose gels
stained with ethidium bromide.
Oligonucleotide primers were chosen using the published sequences
of the human ANX AI [25], Bcl-2, BclX, Bax [26] and 18S RNA [27].
Invitrogen Life Technologies synthesised the primers. The sequences
of the primers, the annealing temperatures and the number of cycles
used for the polymerase chain reaction (PCR) are summarised in
Table 1. One microlitre of the reverse transcribed mRNA mixture
was added directly to the PCR mixture and used for the PCR reac-
tions containing 1 unit of Taq DNA polymerase (Promega, UK). The
resulting PCR-ampli¢ed DNA fragments were con¢rmed by DNA
sequencing. Bands were visualised and scanned using a white/UV
gel camera Imaging densitometer, UVP (Bio-Rad, France).
2.7. Construction of the PDK-6-ANX AI vector and transient
transfection of BZR cells
A cDNA encoding ANX AI was ampli¢ed using the PCR condi-
tions described previously. The cDNA was endowed with a BamHI
restriction site on both its 5P and its 3P extremities (see primer se-
quence Table 1). The PCR product was ligated in-frame into the
BamHI restriction site of the PDK-6 vector [28]. Sense of insertion
was de¢ned using the EcoRV restriction site present at the 3P extrem-
ity (1002 bp) and in the polylinker. The sequence of the PDK-6-ANX
AI construct was veri¢ed by DNA sequencing.
Transfection of the PDK-6-ANX AI vector was carried out follow-
ing the LipofectAMINE procedure as described by the manufacturer
(Invitrogen Life Technologies). Transfected cells were maintained in
DMEM supplemented with 10% FBS. Brie£y, BZR cells (0.2U106
cells per well) were seeded into six-well tissue culture plates and cul-
tured at 37‡C to 40% con£uence. Transfection was performed with
1 Wg of PDK-6-ANX AI plasmid per well or with the empty PDK-6
vector for control. Following incubation, cells were stained or extracts
were prepared and assayed for RNA or protein content.
2.8. Preparation of protein extracts
The medium overlying the cells was discarded and replaced with
ice-cold PBS. BZR cells were harvested by scraping, followed by cen-
trifugation at 400Ug. Cells were lysed in PBS pH 7.4, 0.5% Triton X-
100, 80 mM L-glycerophosphate, 50 mM EGTA, 15 mM MgCl2,
1 mM Na3VO4 and protease inhibitors. Lysates were centrifuged
for 20 min at 15 000Ug, and supernatants diluted in reducing sodium
dodecyl sulfate (SDS) sample bu¡er. Protein content was determined
using the BCA protein quanti¢cation kit (Interchim, France).
2.9. Western blotting of ANX I, caspase-3, poly(ADP-ribose)
polymerase (PARP), Bax and Bcl-xL
Proteins were separated on 10% acrylamide denaturing gels and
transferred to nitrocellulose membranes. Blots were blocked with 10
mM Tris^HCl bu¡er (pH 7.5)/150 mM NaCl (Tris-bu¡ered saline,
TBS) with 5% non-fat dried milk for 45 min, and probed with either
speci¢c anti-ANX I (dilution 1:500), anti-caspase-3 (dilution 1:1000),
anti-PARP (dilution 1:1000), anti-Bax (dilution 1:2000) or anti-Bcl-xL
(dilution 1:2000) antibodies in TBS containing 0.1% Tween 20 and
5% non-fat dried milk. After three washes with TBS 0.1% Tween 20,
the membranes were incubated with an anti-rabbit secondary anti-
body, diluted at 1:4000 in TBS containing 0.1% Tween 20 and 5%
non-fat dried milk. Three washes in TBS 0.1% Tween 20, and two
washes in TBS were performed before visualisation. The ANX AI
polyclonal antibody was a generous gift from Dr Russo-Marie. Cas-
pase-3 (ref. no. 9662) and PARP (ref. no. 9542) antibodies were pur-
chased from Cell Signalling Technology, Ozyme, France, Bax (cat. no.
MS-711-P0) and Bcl-xL (cat. no. MS-1346-P0) antibodies from Neo-
markers.
3. Results
3.1. E¡ect of ANX AI on cell density
To provide evidence that ANX I is involved in the regula-
tion of BZR cell viability, we transfected these cells with a
full-length ANX AI cDNA plasmid construct (Fig. 1A). ANX
AI over-expression was assessed at both the mRNA and pro-
tein levels. Compared to cells transfected with a negative con-
trol plasmid or with an ANX AI antisense plasmid, ANX AI-
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transfected cells displayed a higher mRNA level measured at
24 h and protein level after 48 h (Fig. 1B,C). In these con-
ditions, the limited-proteolysis form of ANX I was also en-
hanced in transfected BZR cells with the full-length ANX AI
cDNA (Fig. 1C), while cell number decreased (Fig. 1C).
3.2. Ceramide e¡ects on cell morphology, cell viability and
ANX AI expression
Incubation of human broncho-alveolar cells (BZR cells)
with C2 ceramide markedly a¡ected their phenotype com-
pared to the inactive dehydroceramide (Fig. 2A). The mor-
phological changes in cells were dose-dependent leading to
disruption of cell monolayer and were associated with
rounded cells. Cells viability was also a¡ected dose-depend-
ently, with a percentage of survival cells relatively low after
treatment with ceramide 40 WM for 24 h (Fig. 2B). In the
same conditions, the expression of the ANX AI protein was
examined using Western blotting with speci¢c antibody. Fol-
lowing C2 ceramide treatment, the full-length ANX AI pro-
tein (37 kDa) level was barely a¡ected, whereas the concen-
Table 1
Gene Sequence Annealing temperature (‡C) Cycles Expected Size
18S RNA (S) 5P-gcgaattcctgccagtagcatatgcttg-3P 55 26 126
(AS) 5P-ggaagcttagaggagcgagcgaccaaagg-3P
Bcl-2 (S) 5P-ttctttgagttcggtggggtc-3P 55 30 304
(AS) 5P-tgcatatttgtttggggcagg-3P
Bclx (S) 5P-ttggacaatggactggttga-3P 55 30 600: BclxS
(AS) 5P-gtagagtggatggtcagtg-3P 800: Bcl-xL
Bax (S) 5P-gacccggtgcctcagga-3P 55 30 294
(AS) 5P-ccggaggaagtccaatgt-3P
ANX AI (S) 5P-cgcggatcctcaaaaatggcaatggtatcag-3P 58 30 1344
(AS) 5P-cgcggatccgcgacgcgttttattttcagctacatagac-3P
PDK6
ANX A1 (cDNA)
Bam HI Bam HI
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Fig. 1. ANX AI over-expression in BZR cells. Diagram of the PDK-6-ANX I vector. ANX AI cDNA expression is under the control of the
SV40 promoter. BamHI and EcoRV sites are delineated by arrows (A). ANX AI over-expression was assessed at the mRNA (B) and protein
(C) levels after 24 and 48 h post-transfection respectively. The percentage of viable cells was determined by the MTT assay relative to control
and percentage of ANX AI expression was determined by densitometric analysis (C). All experiments were performed in triplicate.
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tration of the N-terminally truncated protein (33 kDa) was
dose-dependently increased (Fig. 2B). The degree of the ANX
AI cleaved form paralleled cell death.
3.3. Ceramide e¡ects on cell death
Kinetic study with a C2 ceramide concentration of 40 WM
revealed that cell transformation was quite an early event
(Fig. 3A,B). These cell modi¢cations were associated with
an increase in cytosolic C2 ceramide content (Fig. 3C). To
investigate whether C2 ceramide-induced cell death corre-
sponds to an apoptotic mechanism, apoptosis was further
characterised by mRNA study of speci¢c genes. Compared
to control cells treated with dehydroceramide, Bcl-2 mRNA
was weakly expressed in C2 ceramide-treated cells whereas
 
 
Fig. 2. Dose response of C2 ceramide on cell viability and morphology. BZR cells were treated with various concentrations of C2 ceramide for
24 h. A: Light microscopy (40U). B: Immunoblots were performed to detect ANX AI in BZR cells treated with dehydroceramide or with vari-
ous concentrations of C2 ceramide. The amount in each protein samples was 40 Wg. The percentage of viable cells was determined using the
MTT assay. The deduced percentage of dead cells is shown on the left scale. Experiments were performed in triplicate.
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Bax expression was enhanced (Fig. 4A). Due to di¡erential
splicing, the Bcl-x gene encodes two di¡erent proteins, a long
Bcl-xL and a short Bcl-xS form which display opposite e¡ects
on cell survival (anti-apoptotic and pro-apoptotic respec-
tively). In BZR cells, treatment with C2 ceramide (40 WM)
led to an increase in the pro-apoptotic form while the anti-
apoptotic form was not detected (Fig. 4A). Those gene mod-
i¢cations have been con¢rmed at the protein level using Bax
and Bcl-xL monoclonal antibodies (Fig. 4A). Cell staining
with the DNA counter stain Hoechst dye shows that C2 cer-
amide (40 WM) caused condensation of chromatin in the nu-
cleus while typical apoptotic phospholipid lea£et of cell mem-
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Fig. 3. Kinetics of action of C2 ceramide on BZR cells. BZR cells were treated with C2 ceramide (40 WM) for various times (from 0 to 24 h).
A: Light microscopy (40U). B: The percentage of viable cells was determined using the MTT assay. C: C2 ceramide accumulation in the cyto-
sol by thin layer chromatography. D: Chromatin condensation was de¢ned after 16 h treatment with C2 ceramide (40 WM). Nuclear morphol-
ogy was examined microscopically (40U) using the Hoechst dye. C2 ceramide-induced apoptosis was assessed by £ow cytometry, and analysed
for their staining in the FL1 channel (apoptotic cells labelled with ANX V-FITC) and/or in the FL2 channel (dead cells, positive for PI stain-
ing). Experiments were performed in triplicate.
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brane was evidenced using ANX V-PI double staining (Fig.
3D). Finally, C2 ceramide-treated cells showed increased cas-
pase-3 activation (Fig. 4B), with a marked protease activity
observed by the cleavage of the nuclear enzyme PARP from
6 h after C2 ceramide (40 WM) had been added (Fig. 4B).
3.4. E¡ect of caspase activation on ANX AI-limited proteolysis
To further assess the relationship between ANX AI cleav-
age and caspase activation, BZR cells were pre-treated with
the caspase-related apoptotic inhibitor Z-VAD-fmk. Addition
of Z-VAD-fmk prior to transfection or C2 ceramide treatment
blocked cleavage of ANX AI and impaired apoptotic mor-
phological changes (Fig. 5A).
4. Discussion
Apoptosis is a mechanical programmed cell death triggered
by a large variety of stimuli. However, common biological
and morphological alterations are observed independently of
the initial stimulus. This suggests that most of the signalling
cascade events eventually converge on a restricted number of
critical molecules. Hence, regulation of such switchboard mol-
ecules is of great interest in a strategy of cancer therapy. In
this study, we report for the ¢rst time evidence that cleavage
of the ubiquitous protein ANX AI is a target of the caspase
activation cascade.
Transient transfection of human broncho-alveolar cells with
a plasmid expressing the full-length ANX AI was associated
with a decrease in viable cells. ANX AI has been proposed as
a pro-apoptotic molecule and over-expression of full-length
ANX AI has already been associated with cell death of the
pre-monomyelocytic U937 cell line [13,14]. Nevertheless, we
showed that in BZR cells ANX AI over-expression was asso-
ciated with a processing of limited proteolysis. To investigate
whether over-expression of ANX AI and/or its limited pro-
teolysis were relevant for broncho-alveolar cell death we used
a common apoptosis inducer, i.e. C2 ceramide, to study the
relationship between apoptosis and ANX AI processing. An
in vitro increase in intracellular ceramide concentration is
generally associated with apoptosis induction [16,17]. In
BZR cells, a high concentration of ceramide was required to
induce apoptosis. However, this concentration is dependent
on cell type. In 16-HBE cells, which are not h-Ras transfected
and therefore present a weaker invasive potential [29], a con-
centration of ceramides of 20 WM was su⁄cient to induce cell
death (data not shown). In vitro, an increase in cellular cer-
amide concentration is associated with apoptosis induction.
Other metabolites may also contribute to the diverse action
BclxL
Bcl-2
Bax
18S RNA
Control   C2-ceramide
40 µM
A
C2-ceramide (40 µM) :       C        2h        4h      6h        8h        10h
C2-ceramide (40 µM) :       C        2h        4h      6h        8h        10h
32-35 kDa
17-20 kDa
116 kDa
89 kDa
B
Caspase-3 (inactive)
Caspase-3 (active)
PARP
Cleaved PARP
Corresponding protein 
Corresponding protein 
Fig. 4. C2 ceramide-induced apoptosis in BZR cells. A: BZR cells were treated with C2 ceramide (40 WM) or dehydroceramide (control) for
4 h. Expressions of pro-apoptotic (Bax) and anti-apoptotic (Bcl-2, Bcl-xL) mRNAs were de¢ned by reverse transcription PCR using the 18S
RNA as housekeeping gene. Corresponding Bax and Bcl-xL protein levels were obtained by Western blot (B). BZR cells were treated with C2
ceramide (40 WM) for various times. Cells were lysed and equal amounts of protein (40 Wg) were loaded on a 10% SDS^polyacrylamide gel and
immunoblotted with anti-caspase-3 or PARP antibodies.
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of the sphingolipid class. While ceramide is often considered
as anti-proliferative and pro-apoptotic, its metabolite, sphin-
gosine-1-phosphate, has been implicated as a second messen-
ger in cell growth [30], showing that the balance between these
two sphingolipids is critical for determining cell survival or
death. Determination of ceramide content after 6 h treatment
showed an increase in C2 ceramide in treated cells compared
to untreated cells con¢rming that: (i) C2 ceramide is cell
membrane-permeant and (ii) it is a non-metabolisable com-
pound. This result is also in keeping with the fact that a high
concentration of ceramide is needed to induce apoptosis (Fig.
2) and that this required concentration is dependent on cell
type. This observation raises the critical point that ceramides
might directly regulate their death-activated pathways. Co-in-
cubation with cycloheximide primes the ceramide apoptotic
e¡ect, showing that local protein post-transcriptional regula-
tion is required for ceramide-induced apoptosis. In this set-
ting, a decrease in human broncho-alveolar cell number was
associated with morphological changes: chromatin condensa-
tion and membrane phospholipid £ip-£op, as well as with
cellular changes: caspase-3 activation, PARP cleavage and
adequate Bcl-2, Bcl-xL and Bax variations. In our model sys-
tem, we showed that ceramide-induced apoptosis led to the
ANX AI-limited proteolysis without signi¢cant variation of
the full-length protein (37 kDa). Our work strongly supports
the implication of ANX AI in ceramide-stimulated BZR cells,
and points out the proteolytic cleavage of this protein as an
important mechanism.
Interestingly, along with an increased expression of ANX
AI, we also observed that the level of the cleaved form (33
kDa) was higher in cells transfected with the full-length ANX
AI compared to control and to cells transfected with an anti-
sense cDNA. It has been shown that the N-terminus of ANX
AI can be cleaved at several positions by di¡erent proteases
such as cathepsin D, calpain, plasmin and neutrophil elastase
[21,31]. To provide an explanation for such an e¡ect in our
model system, we proposed ANX AI as a target of a caspase-
activated cascade. In support of this hypothesis, we demon-
strated that the peptide caspase inhibitor Z-VAD-fmk inhib-
ited both ceramide-induced apoptosis and ANX AI-limited
proteolysis. Therefore, we showed for the ¢rst time that cas-
pase cascade inhibition is associated with a decrease in ANX
AI-limited proteolysis. While further experiments are needed
to address ANX AI processing, it seems unlikely that ANX
AI is cleaved by a direct action of either group I (caspases 1,
2, 4, 5, 11), group II (caspases 6, 8, 9, 10) or group III (cas-
pases 2, 3, 7) caspases since their recognition motifs are not
present on the ANX AI translated sequence [25].
Considering that di¡erent properties might be bound to
ANX AI multi-forms, we then considered the e¡ect of such
a cleavage on cell physiology. Over-expression of full-length
ANX AI has been associated with cell death and caspase-3
activation [14]. Knowing that cPLA2 is a substrate of caspase-
3 [32], this indirect anti-PLA2 mechanism of ANX AI should
lead to a decrease of the anti-apoptotic molecule prostaglan-
din E2 (PGE2) production and therefore reinforce the ANX
AI pro-apoptotic potential. Furthermore, caspase-3 also pro-
motes ANX AI-limited proteolysis, leading to the N-termi-
nally deleted ANX AI which still exhibits anti-PLA2 activity
[33] and to the N-terminus peptide release presenting the
EQEYV sequence which can act as a decoy substrate at the
receptor level, blocking the association of Grb2, p21 (Ras)
and Raf [34,35] and subsequently downstream activation of
enzymes such as cPLA2. This inhibitory e¡ect is in keeping
with other studies showing that ANX AI-derived N-terminus
peptide dose-dependently inhibits cytochrome oxidase 2 ex-
pression and PGE2 production [36] as well as that the N-
terminus ANX AI peptide increases susceptibility to apoptosis
[14]. Consequently, the assumed indirect cleavage of ANX AI
via caspase activation leads the cell into a perpetuated circle
ending with cell death. ANX AI could play a major role in
tumour growth through the combination of several properties
acting in concert : (1) on cell proliferation, which could be
linked to its MAPK inhibitory e¡ect, (2) on in£ammation,
Control  A C2-ceramide + ZVAD  Transfected cells + ZVAD 
B
 
37  kDa 
33  kDa 
Annexin A1   
Control Transfected cells 
+ ZVAD 
C2-ceramide 
+ ZVAD 
Fig. 5. C2 ceramide-induced apoptosis promotes ANX AI cleavage. BZR cells were pre-treated or not for 1 h with the caspase family inhibitor
Z-VAD-fmk before addition of C2 ceramide 40 WM or transfection with the PDK-6-ANX I vector. A: Light microscopic examination of cells.
B: Western blot analysis of ANX AI. The amount of protein loaded in each sample was 40 Wg. Experiments were performed in triplicate.
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through its anti-PLA2 activity whether via direct [1] or indi-
rect [37] mechanisms as well as through the decoy action of
the N-terminus peptide [34^36] and the degradation of PLA2
by caspase-3 [32], and (3) on apoptosis by activation of the
caspase-3 protease [14].
Most cancer cells continually develop abnormalities. Thus,
a potential therapy that targets one speci¢c cell type or cancer
state may not eventually be e⁄cacious. By contrast, in this
study we provided evidence that ANX I is one potential in-
termediate molecule involved in the activation of biochemical
programmes of cell growth arrest. We thus speculate that in
human broncho-alveolar cells, the ceramide-induced cascade
leading to cell death may be magni¢ed through the ubiquitous
intermediate ANX I involved in all mechanisms listed above.
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